Document Detail


Mechanisms of lipotoxicity in the cardiovascular system.
MedLine Citation:
PMID:  23054891     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Cardiovascular diseases account for approximately one third of all deaths globally. Obese and diabetic patients have a high likelihood of dying from complications associated with cardiovascular dysfunction. Obesity and diabetes increase circulating lipids that upon tissue uptake, may be stored as triglyceride, or may be metabolized in other pathways, leading to the generation of toxic intermediates. Excess lipid utilization or activation of signaling pathways by lipid metabolites may disrupt cellular homeostasis and contribute to cell death, defining the concept of lipotoxicity. Lipotoxicity occurs in multiple organs, including cardiac and vascular tissues, and a number of specific mechanisms have been proposed to explain lipotoxic tissue injury. In addition, recent data suggests that increased tissue lipids may also be protective in certain contexts. This review will highlight recent progress toward elucidating the relationship between nutrient oversupply, lipotoxicity, and cardiovascular dysfunction. The review will focus in two sections on the vasculature and cardiomyocytes respectively.
Authors:
Adam R Wende; J David Symons; E Dale Abel
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Current hypertension reports     Volume:  14     ISSN:  1534-3111     ISO Abbreviation:  Curr. Hypertens. Rep.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-06     Completed Date:  2013-04-17     Revised Date:  2014-06-12    
Medline Journal Info:
Nlm Unique ID:  100888982     Medline TA:  Curr Hypertens Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  517-31     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Blood Vessels / metabolism
Cardiovascular Diseases / complications,  metabolism*
Diabetes Mellitus, Type 2 / complications,  metabolism
Humans
Lipid Metabolism*
Myocytes, Cardiac / metabolism
Obesity / complications,  metabolism
Grant Support
ID/Acronym/Agency:
K99 HL111322/HL/NHLBI NIH HHS; K99 HL111322/HL/NHLBI NIH HHS; R01 DK092065/DK/NIDDK NIH HHS; R01 DK092065/DK/NIDDK NIH HHS; R01 HL108379/HL/NHLBI NIH HHS; R01HL108379/HL/NHLBI NIH HHS; R15 HL091493/HL/NHLBI NIH HHS; R15 HL091493/HL/NHLBI NIH HHS; U01 HL087947/HL/NHLBI NIH HHS; U01 HL087947/HL/NHLBI NIH HHS
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Preventive Effects of Egyptian Sweet Marjoram (Origanum majorana L.) Leaves on Haematological Change...
Next Document:  Birth Weight and Childhood Blood Pressure.